OBJECTIVE
Alzheimer's disease (AD) continues to be the leading cause of dementia worldwide, due to its complicated, multifactorial pathophysiology. To shift the AD paradigm from reactive to proactive, from a specific time to a precision medicine intervention strategy, this study examines the role of artificial intellig...
Namra Aziz, Kritika Sachan, Anuradha Singh et al.· Current Drug Targets· 0 citations
INTRODUCTION
Parkinson's disease (PD) is a progressive neurodegenerative disorder driven by oxidative stress, neuroinflammation, and mitochondrial dysfunction. Although flavonoids such as luteolin and fisetin exhibit strong antioxidant and neuroprotective properties, their therapeutic utility is limited by poor solubil...
Namra Aziz, Gagandeep Singh Basra, A. Wal et al.· Current Neurovascular Resear...· 0 citations
AI has proven to be very helpful in predicting therapeutic targets, optimizing gene vectors, and customizing dementia treatment plans, and it also makes gene-target prediction, nanocarrier optimization, and post-treatment monitoring easier.
A. Wal, M. Shukla, Pranay Wal et al.· Current Gene Therapy· 0 citations
INTRODUCTION
The demand for inventive approaches to drug discovery has increased due to the rising costs, time, and failure rates in pharmaceutical research. Large Language Models (LLMs), with their sophisticated natural language processing and generative capabilities, have become potent instruments that have the poten...
Pranay Wal, M. Shukla, Kritika Sachan et al.· Current Computer - Aided Dru...· 0 citations
The results indicate the potential for substantial improvements in current pharmacovigilance systems through the use of AI-based models that can identify latent relationships and deliver safety alerts in near-real time.
C. R. Darwin, Meruva Sathish Kumar, S. Marakatham et al.· Current Drug Safety· 0 citations
Novel instruments, such as artificial intelligence, molecular modelling, and systems pharmacology, may further aid the optimisation of ligand selection, carrier design, and personalised therapeutic development in GPCR-targeted therapeutic treatments.
Pranay Wal, Jyotsana Dwivedi, K. Khairunnisa et al.· Current Drug Targets· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
